

Kidney Cancer GCOM 8 minutes

Kidney Cancer update – committee meeting 8 minutes

Date: 12/12/2024

Location: Virtual

Minutes: Final

Committee members present:		
Ana Semedo	Vice Chair	Present for items 1–6
Axel Bex	Urological Surgeon	Present for items 1-3.1, 4-6
Janet Brown	Medical Oncologist	Present for items 2-5
Amarnath Challapalli	Clinical Oncologist (general)	Present for items 2-3
John Connolly	Lay Member	Present for items 1–6
David Cullen	Urology Cancer Nurse	Present for items 1–6
Geraldine Fox	Lay Member	Present for items 1–6
David Mole	Nephrologist (co-opted member)	Present for items 1–6
Ankit Rao	Medical Oncologist	Present for items 1–6
Sandeep Singh Randhawa	General Practitioner	Present for items 1–6
Grant Stewart	Topic Adviser	Present for items 1-3.1, 4-6
Sam Withey	Diagnostic Radiologist	Present for items 1–6
Rose Woodward	Lay Member	Present for items 1–6

In attendance NICE:		
Marie Harrisingh	Topic Lead	Present for items 1–6
Sarah Boyce	Senior Technical Analyst	Present for items 1–4
Victoria Carter	Implementation Support Manager	Present for items 1–6
Danielle Conroy	Project Manager	Present for items 1–6
Lindsay Claxton	Health Economics Adviser	Present for items 1–6
Olivia Crane	Senior Technical Analyst	Present for items 5-6
Benjamin Gregory	Business Analyst, Resource Impact	Present for items 3-5
James Hall	Senior Medical Editor	Present for items 1–6
Sarah Matthews	Technical Analyst (observing)	Present for items 1-4
Lina Manounah	Technical Analyst	Present for items 5-6

Kidney Cancer GCOM 8 minutes

Agnesa Mehmeti	Technical Analyst	Present for items 1–5
Katherine Saxby	Medicines Adviser, Medicines Optimisation	Present for item 3
Hannah Tebbs	Senior Health Economist	Present for items 1–6
Fernando Zanghelini	Technical Analyst	Present for items 1–4
Yuanyuan Zhang	Health Economist	Present for items 1-6

Apologies:

Baljit Singh	Committee Chair
Lisa Browning	Histopathologist
Amy Clifford	Clinical Oncologist (SABR)
Stuart Evans	Oncology Pharmacist, Committee Member
Fayiza Habeeb	Lead Nurse Practitioner, Committee Member
Maxine Tran	Urological Surgeon, Committee Member
Tze Min Wah	Interventional Radiologist, Committee Member

1. Welcome, Introductions and DOIs

The Vice Chair, Ana Semedo (AS) welcomed the committee members and NICE attendees to the 8th committee meeting for the NICE Kidney Cancer guideline.

AS informed attendees that apologies had been received as noted above. AS asked all committee members to verbally declare any new interests.

No new interests were declared but AS reminded the group of the following recorded interests which are relevant to the day's discussion:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Axel Bex	Consultant Urologist and Clinical Lead Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Specialist Centre for Kidney	Oza, Bhavna, Eisen, Tim, Frangou, Eleni et al. (2022) External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 40(16): 1772-178. Declared	Specific, Direct -non-financial professional and personal	Declare and partial exclusion Participate in discussion but withdraw for drafting recommendations.

Kidney Cancer GCOM 8 minutes

	Cancer			
Axel Bex	Consultant Urologist and Clinical Lead Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer	Klatte, T., Gallagher, K.M., Afferi, L. et al. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. BMC Med 17, 182 (2019). Declared	Specific, Direct -non-financial professional and personal	Declare and partial exclusion Participate in discussion but withdraw for drafting recommendations.
Grant Stewart	Professor of Surgical Oncology, University of Cambridge, Honorary Consultant in Urological Surgery, Cambridge University Hospitals NHS Foundation Trust	Usher-Smith, J.A., Li, L., Roberts, L., Harrison, H., Rossi, S.H., Sharp, S.J., Coupland, C., Hippisley-Cox, J., Griffin, S.J., Klatte, T. and Stewart, G.D. (2022), Risk models for recurrence and survival after kidney cancer: a systematic review. BJU Int, 130: 562-579. https://doi.org/10.1111/bju.15673	Specific, Direct -non-financial professional and personal	Declare and partial exclusion Participate in discussion but withdraw for drafting recommendations.
Grant Stewart	Professor of Surgical Oncology, University of Cambridge, Honorary Consultant in Urological Surgery, Cambridge University Hospitals NHS Foundation Trust	Author on papers about Leibovich prediction model for people with non-metastatic KC): Vasudev, Naveen S, Hutchinson, Michelle, Trainor, Sebastian et al. (2020) UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time. Urology 136: 162-168 Oza, Bhavna, Eisen, Tim, Frangou, Eleni et al. (2022) External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in	Specific, Direct -non-financial professional and personal	Declare and partial exclusion Participate in discussion but withdraw for drafting recommendations.

		<p>Renal Cell Cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 40(16): 1772-1782</p> <p>Um, In Hwa, Scott-Hayward, Lindsay, Mackenzie, Monique et al. (2020) Computerized Image Analysis of Tumor Cell Nuclear Morphology Can Improve Patient Selection for Clinical Trials in Localized Clear Cell Renal Cell Carcinoma. Journal of pathology informatics 11: 35</p>		
Grant Stewart	<p>Professor of Surgical Oncology, University of Cambridge, Honorary Consultant in Urological Surgery, Cambridge University Hospitals NHS Foundation Trust</p>	<p>Klatte, T., Gallagher, K.M., Afferi, L. et al. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. BMC Med 17, 182 (2019). https://doi.org/10.1186/s12916-019-1419-1</p>	<p>Specific, Direct -non-financial professional and personal</p>	<p>Declare and partial exclusion</p> <p>Participate in discussion but withdraw for drafting recommendations.</p>

Axel Bex (AB) and Grant Stewart (GS) were authors on papers included in the evidence review being discussed. It was agreed that the member could stay for the discussion of the evidence of review question 2a(i) but would need to step out whilst recommendations were being made.

Finally, the minutes from committee 7 were checked and agreed to be an accurate record.

2. RQ2c (prognostic models for non-metastatic kidney cancer):

- Revisit methods and evidence**

The Chair introduced Agnesa Mehmeti (AM), Technical Analyst who presented a summary of the clinical evidence on clear cell and all types of renal cell carcinoma (RCC) and for papillary and chromophobe RCC which was originally presented to the group at meeting 7.

3. RQ2c (prognostic models for non- metastatic kidney cancer):

- 3.1 Committee discussion**

- **3.2 Revisit draft recommendations**
- **3.3 Health and Inequality considerations**

Marie Harrisingh (MH), Topic Lead drove the committee discussion on the evidence presented and asked the committee for their expert input on several queries. After a productive discussion AS thanked the committee for their response and moved the discussion on to the drafting of recommendations.

AB and GS left the meeting at this point due to a conflict of interest.

With support from the committee, the NICE team were able to revise initial wording drafted at the previous meeting for use of prognostic models for non-metastatic kidney cancer.

The committee also considered any equality and health inequality issues in this area and drafted research recommendations before AS moved on to the next item on the agenda.

4. RQ2c (prognostic models for metastatic RCC):

- **Presentation of clinical evidence for IMDC**
- **Presentation of clinical evidence for MSKCC**
- **Presentation of clinical evidence for Meet-Uro**
- **Committee discussion**
- **Draft recommendations**

AB and GS rejoined the meeting.

The Chair introduced Fernando Zanghelini (FZ), Technical Analyst who presented the clinical evidence looking at different prognostic models for predicting outcomes in metastatic renal cell carcinoma (RCC).

The committee had the opportunity to discuss what was presented and ask questions.

Taking input from the committee to draft the initial wording, the NICE team were able to draft recommendations and research recommendations that would be taken away for further edits.

AS thanked the committee for their input.

5. RQ5b (follow-up and monitoring for previously treated renal cell carcinoma):

- **Discussion of clinical evidence**

The Chair introduced Lina Manounah (LM), Technical Analyst who presented the evidence on follow-up and monitoring.

The committee had the opportunity to discuss what was presented, ask questions and consider any equality and health inequality issues.

Drafting of recommendations was deferred until the results of the economic modelling are available.

6. Next steps and AOB

AS summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, AS brought the meeting to a close.

Date of next meeting: 27/01/2025

Location of next meeting: Virtual